Aim immunotech to participate in a solve m.e. signature event: ‘long covid: research, policy, and economic impact' on may 19, 2022

Ocala, fla., may 12, 2022 (globe newswire) -- aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, today announced it will participate in the solve m.e. diagnostics signature event “long covid: research, policy, and economic impact,” being held virtually and in new york, n.y. on thursday, may 19, 2022.
AIM Ratings Summary
AIM Quant Ranking